

## Hong Kong's Viva Biotech establishes Boston branch, marking another milestone in global expansion

11 December 2024 | News

**To further enhance and deepen international collaboration networks**



Viva Biotech Holdings Group has announced the official establishment of its new branch in Boston, US. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the company's global expansion strategy.

Hong Kong-based Viva Biotech aims to further enhance and deepen international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services, from drug discovery and preclinical development to commercial manufacturing, for clients worldwide.

Boston, often recognised as a top life science cluster, boasts a globally renowned ecosystem for biopharmaceutical innovation. Viva Biotech's Boston branch is situated in Cambridge, Massachusetts, placing it at the forefront of global biopharma innovation. Surrounded by world-class research institutions like Harvard University and Massachusetts Institute of Technology, as well as being the home to numerous biotech giants and innovative startups, this location offers unparalleled access to cutting-edge scientific advancements and collaborative opportunities.

With the continuous business expansion and the growing market demands, Viva Biotech has decided to establish a branch to further enhance its market coverage and service capabilities in North America.

The Boston branch will serve as a crucial hub within Viva Biotech's global network, seamlessly connecting operations in China, the United States, the United Kingdom, Europe, and other regions. Together, these interconnected entities will form an efficient global operational system, poised to respond swiftly and precisely to the evolving landscape of drug discovery and development, as well as the increasingly diverse needs of our clients.

Dr Cheney Mao, Chairman and CEO of Viva Biotech stated: "Moving forward, we will further expand our CRO and CDMO business, strengthening early-stage project capabilities to drive future growth. It is our crucial strategy to establish the branch in Boston to deepen our international markets presence and enhance our global competitiveness. We are building a more open and collaborative global service network to provide flexible and efficient comprehensive solutions for our partners. Looking ahead, Viva Biotech will continue to advance its globalization strategy, enhancing its one-stop drug discovery and manufacturing capabilities to contribute to the development of the global biopharmaceutical industry."

Dr Derek Ren, CEO of Viva Biotech (Shanghai) stated, "The establishment of the Boston branch not only strategically solidifies Viva Biotech's business layout but also serves as a key hub connecting us to global innovation resources, which will strengthen our strategic depth in international markets."